Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Endocrinology  |  Musculoskeletal  |  Rheumatology

Search Medical Condition
Please enter condition
Please choose location from dropdown

Acromegaly Clinical Trials

A listing of Acromegaly medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (33) clinical trials

Lanreotide Levels in Acromegaly

Recently lanreotide (a somatostatin analog) has come into the US marketplace as a commercially available medication approved by the FDA for the treatment of acromegaly. Blood levels in patients getting this drug are unknown and it may be critical to know the levels in patients whose symptoms are poorly controlled. ...

Phase N/A

Estrogen Treatment in Acromegalic Women

This will be a canadian multicenter study with a randomized, double-blind, placebo-controlled design, to assess the efficacy and safety of adjuvant alesse in female acromegalic patients with suboptimal response to sandostatin LAR treatment.

Phase

Measurement of Outcome of Surgical Treatment in Patients With Acromegaly

PROTOCOL OUTLINE: Blood samples are collected and assessed for growth hormone and IGF-I by polyclonal radioimmunoassay (RIA) and immunoradiometric assay (IRMA). Growth hormone is measured at baseline and 60, 90, and 120 minutes after a 100 g glucose drink. Serum glucose is measured at baseline and at 2 hours post ...

Phase N/A

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.

This is a multi-center, open label, phase IV study to provide continued supply of pasireotide to patients being treated in a current Novartis-sponsored, Oncology CD&MA study and who are benefiting from treatment with pasireotide. Eligible patients are to be consented and can then continue treatment with pasireotide in this protocol. ...

Phase

An Investigation of Pituitary Tumors and Related Hypothalmic Disorders

There are a variety of tumors affecting the pituitary gland; The gene(s) involved in the pathogenesis of these tumors are largely not known; their possible association with other developmental defects or inheritance pattern(s) has not been investigated. The present study serves as a (i) screening/training, and, (ii) a research protocol. ...

Phase N/A

Rehabilitation Program in Patients With Acromegaly

Acromegaly is a rare, chronic, disabling disease of endocrine origin that causes several debilitating systemic dysfunctions due to the excessive production of growth hormone (GH) and insulin-like growth factor I (IGF-I) (Gadelha et al., 2017). In 98% of cases, the disease is caused by a sporadic somatotropinoma. Sporadic somatotropinomas are ...

Phase N/A

Muscle in Acromegaly and Cushing's Syndrome

Prior chronic exposure to glucocorticoids or growth hormone (GH) determines fat infiltration and persistent impairment of muscle structure in "cured" patients with CS or acromegaly, respectively. All this leads to irreversible changes in muscle strength and performance, markedly affecting morbidity and quality of life of these patients. In particular, muscle ...

Phase N/A

Acromegaly: Patient And Physician Perspectives

The purpose of the study is to assess the experiences of individuals with acromegaly who are receiving injections as part of their treatment regimen. Another objective of the study is to compare the patients' perception with their doctors' perceptions. The answers are important to help researchers and physicians understand what ...

Phase N/A

Strict IGF-1 Control in Acromegaly

Acromegaly is a rare, chronic, and debilitating disease, usually caused by a benign tumor on the pituitary gland, which leads to excessive production of growth hormone (GH). GH excess in turn causes overproduction of another hormone called insulin-like growth factor-1 (IGF-1). IGF-1 levels are currently the most widely accepted measure ...

Phase

Safety Tolerability and Efficacy of IONIS-GHR-LRx in up to 42 Adult Patients With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands

This short-term study will assess changes in serum insulin-like growth factor 1 (IGF-1) over a 16-week treatment period in a patient population diagnosed with Acromegaly being treated with Long-acting Somatostatin Receptor Ligands (SRL)

Phase